
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Impact of Nutritional Supplementation on Sleep Quality
Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of Sleep.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 20, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Atlantia Food Clinical Trials Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of a Nutritional Supplement on Gut Microbiota in Adults
Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Dysbiosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Atlantia Food Clinical Trials Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bonafide-HF3.0
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Lindus Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Hot Flash and Night Sweat Virtual Study
Details : Bonafide-HF3.0 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 04, 2024
Lead Product(s) : Bonafide-HF3.0
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Lindus Health
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bonafide Pollen
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Bonafide Health
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Pharmavite will expand its portfolio of women's health by including Relizen (bonafide pollen), a plant-based & hormone-free supplement, which is safe to use for menopause relief.
Product Name : Relizen
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 30, 2023
Lead Product(s) : Bonafide Pollen
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Bonafide Health
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Triglyceride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Atlantia Food Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of a Nutritional Supplement on Mental Wellness in Adults
Details : Triglyceride is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Triglyceride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Atlantia Food Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : JDS-HF
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women
Details : JDS-HF is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hot Flashes.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
April 14, 2023
Lead Product(s) : JDS-HF
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Midwest Center for Metabolic and Cardiovascular Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Select Nutrients From Two Formulations of a Multivitamin/Mineral Supplement
Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Midwest Center for Metabolic and Cardiovascular Research
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : S-Equol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Biofortis Mérieux Nutriscience
Deal Size : Inapplicable
Deal Type : Inapplicable
A Nutritional Supplement on Vasomotor Symptoms in Women
Details : S-equol is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
August 18, 2020
Lead Product(s) : S-Equol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Biofortis Mérieux Nutriscience
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Melatonin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : KGK Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2019
Lead Product(s) : Melatonin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : KGK Science
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Midwest Center for Metabolic and Cardiovascular Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of EPA + DHA in a SMEDS Formulation
Details : Eicosapentaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2018
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Midwest Center for Metabolic and Cardiovascular Research
Deal Size : Inapplicable
Deal Type : Inapplicable
